nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexrazoxane—TOP2A—Epirubicin—ovarian cancer	0.385	0.653	CbGbCtD
Dexrazoxane—TOP2A—Doxorubicin—ovarian cancer	0.204	0.347	CbGbCtD
Dexrazoxane—TOP2B—myometrium—ovarian cancer	0.00774	0.0762	CbGeAlD
Dexrazoxane—TOP2B—embryo—ovarian cancer	0.00745	0.0733	CbGeAlD
Dexrazoxane—TOP2B—uterine cervix—ovarian cancer	0.00602	0.0593	CbGeAlD
Dexrazoxane—TOP2B—decidua—ovarian cancer	0.00574	0.0565	CbGeAlD
Dexrazoxane—TOP2A—myometrium—ovarian cancer	0.00569	0.0561	CbGeAlD
Dexrazoxane—TOP2B—endometrium—ovarian cancer	0.00545	0.0537	CbGeAlD
Dexrazoxane—TOP2B—gonad—ovarian cancer	0.00505	0.0498	CbGeAlD
Dexrazoxane—TOP2B—uterus—ovarian cancer	0.00502	0.0494	CbGeAlD
Dexrazoxane—TOP2B—female reproductive system—ovarian cancer	0.00451	0.0444	CbGeAlD
Dexrazoxane—TOP2A—uterine cervix—ovarian cancer	0.00443	0.0436	CbGeAlD
Dexrazoxane—TOP2B—bone marrow—ovarian cancer	0.00426	0.042	CbGeAlD
Dexrazoxane—TOP2A—decidua—ovarian cancer	0.00422	0.0416	CbGeAlD
Dexrazoxane—TOP2B—female gonad—ovarian cancer	0.00411	0.0404	CbGeAlD
Dexrazoxane—TOP2B—vagina—ovarian cancer	0.00408	0.0402	CbGeAlD
Dexrazoxane—TOP2A—endometrium—ovarian cancer	0.00401	0.0395	CbGeAlD
Dexrazoxane—TOP2A—uterus—ovarian cancer	0.00369	0.0364	CbGeAlD
Dexrazoxane—TOP2B—testis—ovarian cancer	0.00364	0.0359	CbGeAlD
Dexrazoxane—TOP2A—bone marrow—ovarian cancer	0.00313	0.0309	CbGeAlD
Dexrazoxane—TOP2A—female gonad—ovarian cancer	0.00302	0.0297	CbGeAlD
Dexrazoxane—TOP2A—vagina—ovarian cancer	0.003	0.0296	CbGeAlD
Dexrazoxane—TOP2A—testis—ovarian cancer	0.00268	0.0264	CbGeAlD
Dexrazoxane—TOP2B—lymph node—ovarian cancer	0.00264	0.026	CbGeAlD
Dexrazoxane—TOP2A—lymph node—ovarian cancer	0.00194	0.0191	CbGeAlD
Dexrazoxane—TOP2A—Docetaxel—Paclitaxel—ovarian cancer	0.00185	0.219	CbGdCrCtD
Dexrazoxane—TOP2A—Irinotecan—Topotecan—ovarian cancer	0.00159	0.187	CbGdCrCtD
Dexrazoxane—TOP2A—Vindesine—Vinorelbine—ovarian cancer	0.00118	0.139	CbGdCrCtD
Dexrazoxane—TOP2A—G0 and Early G1—RBL2—ovarian cancer	0.00105	0.0933	CbGpPWpGaD
Dexrazoxane—TOP2A—Paclitaxel—Docetaxel—ovarian cancer	0.000926	0.109	CbGdCrCtD
Dexrazoxane—TOP2A—Vincristine—Vinorelbine—ovarian cancer	0.000636	0.075	CbGdCrCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—TP63—ovarian cancer	0.000565	0.05	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—BARD1—ovarian cancer	0.00053	0.0469	CbGpPWpGaD
Dexrazoxane—TOP2A—Vinblastine—Vinorelbine—ovarian cancer	0.000512	0.0603	CbGdCrCtD
Dexrazoxane—TOP2A—G0 and Early G1—CCNE1—ovarian cancer	0.000471	0.0417	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—YAP1—ovarian cancer	0.000465	0.0411	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—FASN—ovarian cancer	0.000379	0.0335	CbGpPWpGaD
Dexrazoxane—Cardiac failure congestive—Epirubicin—ovarian cancer	0.000348	0.0012	CcSEcCtD
Dexrazoxane—Fatigue—Vinorelbine—ovarian cancer	0.000348	0.0012	CcSEcCtD
Dexrazoxane—Angiopathy—Paclitaxel—ovarian cancer	0.000347	0.0012	CcSEcCtD
Dexrazoxane—Pain—Vinorelbine—ovarian cancer	0.000345	0.00119	CcSEcCtD
Dexrazoxane—Constipation—Vinorelbine—ovarian cancer	0.000345	0.00119	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000344	0.00119	CcSEcCtD
Dexrazoxane—Phlebitis—Doxorubicin—ovarian cancer	0.000339	0.00117	CcSEcCtD
Dexrazoxane—Asthenia—Topotecan—ovarian cancer	0.000339	0.00117	CcSEcCtD
Dexrazoxane—Alopecia—Paclitaxel—ovarian cancer	0.000338	0.00117	CcSEcCtD
Dexrazoxane—Vomiting—Chlorambucil—ovarian cancer	0.000337	0.00116	CcSEcCtD
Dexrazoxane—Agranulocytosis—Docetaxel—ovarian cancer	0.000337	0.00116	CcSEcCtD
Dexrazoxane—Blood alkaline phosphatase increased—Doxorubicin—ovarian cancer	0.000336	0.00116	CcSEcCtD
Dexrazoxane—Mental disorder—Paclitaxel—ovarian cancer	0.000335	0.00116	CcSEcCtD
Dexrazoxane—Pruritus—Topotecan—ovarian cancer	0.000334	0.00115	CcSEcCtD
Dexrazoxane—Malnutrition—Paclitaxel—ovarian cancer	0.000333	0.00115	CcSEcCtD
Dexrazoxane—Erythema—Paclitaxel—ovarian cancer	0.000333	0.00115	CcSEcCtD
Dexrazoxane—Feeling abnormal—Vinorelbine—ovarian cancer	0.000333	0.00115	CcSEcCtD
Dexrazoxane—Asthenia—Melphalan—ovarian cancer	0.000332	0.00115	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00033	0.00114	CcSEcCtD
Dexrazoxane—Pruritus—Melphalan—ovarian cancer	0.000327	0.00113	CcSEcCtD
Dexrazoxane—Haemoglobin—Docetaxel—ovarian cancer	0.000326	0.00112	CcSEcCtD
Dexrazoxane—Haemorrhage—Docetaxel—ovarian cancer	0.000324	0.00112	CcSEcCtD
Dexrazoxane—Diarrhoea—Topotecan—ovarian cancer	0.000323	0.00112	CcSEcCtD
Dexrazoxane—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.000322	0.00111	CcSEcCtD
Dexrazoxane—Urticaria—Vinorelbine—ovarian cancer	0.000321	0.00111	CcSEcCtD
Dexrazoxane—Abdominal pain—Vinorelbine—ovarian cancer	0.000319	0.0011	CcSEcCtD
Dexrazoxane—Body temperature increased—Vinorelbine—ovarian cancer	0.000319	0.0011	CcSEcCtD
Dexrazoxane—Oedema peripheral—Docetaxel—ovarian cancer	0.000319	0.0011	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Docetaxel—ovarian cancer	0.000318	0.0011	CcSEcCtD
Dexrazoxane—Hyponatraemia—Epirubicin—ovarian cancer	0.000317	0.0011	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.000317	0.028	CbGpPWpGaD
Dexrazoxane—Diarrhoea—Melphalan—ovarian cancer	0.000316	0.00109	CcSEcCtD
Dexrazoxane—Nausea—Chlorambucil—ovarian cancer	0.000315	0.00109	CcSEcCtD
Dexrazoxane—Dizziness—Topotecan—ovarian cancer	0.000312	0.00108	CcSEcCtD
Dexrazoxane—Tremor—Paclitaxel—ovarian cancer	0.000312	0.00108	CcSEcCtD
Dexrazoxane—TOP2A—Idarubicin—Epirubicin—ovarian cancer	0.00031	0.0365	CbGdCrCtD
Dexrazoxane—TOP2A—Daunorubicin—Epirubicin—ovarian cancer	0.00031	0.0365	CbGdCrCtD
Dexrazoxane—TOP2A—Doxorubicin—Epirubicin—ovarian cancer	0.00031	0.0365	CbGdCrCtD
Dexrazoxane—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000309	0.00107	CcSEcCtD
Dexrazoxane—Anaemia—Paclitaxel—ovarian cancer	0.000308	0.00106	CcSEcCtD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—APC—ovarian cancer	0.000302	0.0267	CbGpPWpGaD
Dexrazoxane—Cardiac disorder—Docetaxel—ovarian cancer	0.000301	0.00104	CcSEcCtD
Dexrazoxane—Vomiting—Topotecan—ovarian cancer	0.0003	0.00104	CcSEcCtD
Dexrazoxane—Malaise—Paclitaxel—ovarian cancer	0.0003	0.00104	CcSEcCtD
Dexrazoxane—Syncope—Paclitaxel—ovarian cancer	0.000298	0.00103	CcSEcCtD
Dexrazoxane—Leukopenia—Paclitaxel—ovarian cancer	0.000298	0.00103	CcSEcCtD
Dexrazoxane—Blood creatinine increased—Epirubicin—ovarian cancer	0.000296	0.00102	CcSEcCtD
Dexrazoxane—Headache—Topotecan—ovarian cancer	0.000296	0.00102	CcSEcCtD
Dexrazoxane—Angiopathy—Docetaxel—ovarian cancer	0.000294	0.00102	CcSEcCtD
Dexrazoxane—Vomiting—Melphalan—ovarian cancer	0.000294	0.00101	CcSEcCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—ovarian cancer	0.000294	0.026	CbGpPWpGaD
Dexrazoxane—Hyponatraemia—Doxorubicin—ovarian cancer	0.000293	0.00101	CcSEcCtD
Dexrazoxane—Loss of consciousness—Paclitaxel—ovarian cancer	0.000292	0.00101	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Docetaxel—ovarian cancer	0.000292	0.00101	CcSEcCtD
Dexrazoxane—Cough—Paclitaxel—ovarian cancer	0.00029	0.001	CcSEcCtD
Dexrazoxane—Asthenia—Vinorelbine—ovarian cancer	0.00029	0.001	CcSEcCtD
Dexrazoxane—TOP2A—Epirubicin—Doxorubicin—ovarian cancer	0.000287	0.0338	CbGdCrCtD
Dexrazoxane—TOP2A—Idarubicin—Doxorubicin—ovarian cancer	0.000287	0.0338	CbGdCrCtD
Dexrazoxane—TOP2A—Daunorubicin—Doxorubicin—ovarian cancer	0.000287	0.0338	CbGdCrCtD
Dexrazoxane—Alopecia—Docetaxel—ovarian cancer	0.000286	0.000989	CcSEcCtD
Dexrazoxane—Pruritus—Vinorelbine—ovarian cancer	0.000286	0.000987	CcSEcCtD
Dexrazoxane—Breast disorder—Epirubicin—ovarian cancer	0.000285	0.000986	CcSEcCtD
Dexrazoxane—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000284	0.000982	CcSEcCtD
Dexrazoxane—Mental disorder—Docetaxel—ovarian cancer	0.000284	0.00098	CcSEcCtD
Dexrazoxane—Myalgia—Paclitaxel—ovarian cancer	0.000283	0.000978	CcSEcCtD
Dexrazoxane—Erythema—Docetaxel—ovarian cancer	0.000282	0.000974	CcSEcCtD
Dexrazoxane—Malnutrition—Docetaxel—ovarian cancer	0.000282	0.000974	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000281	0.000972	CcSEcCtD
Dexrazoxane—Nausea—Topotecan—ovarian cancer	0.00028	0.000968	CcSEcCtD
Dexrazoxane—Discomfort—Paclitaxel—ovarian cancer	0.00028	0.000967	CcSEcCtD
Dexrazoxane—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000279	0.000962	CcSEcCtD
Dexrazoxane—Dry mouth—Paclitaxel—ovarian cancer	0.000277	0.000957	CcSEcCtD
Dexrazoxane—Diarrhoea—Vinorelbine—ovarian cancer	0.000276	0.000954	CcSEcCtD
Dexrazoxane—Nausea—Melphalan—ovarian cancer	0.000274	0.000948	CcSEcCtD
Dexrazoxane—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000274	0.000946	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—RBL2—ovarian cancer	0.000274	0.0242	CbGpPWpGaD
Dexrazoxane—Dysphagia—Epirubicin—ovarian cancer	0.000273	0.000943	CcSEcCtD
Dexrazoxane—Infection—Paclitaxel—ovarian cancer	0.00027	0.000932	CcSEcCtD
Dexrazoxane—Shock—Paclitaxel—ovarian cancer	0.000267	0.000923	CcSEcCtD
Dexrazoxane—Dizziness—Vinorelbine—ovarian cancer	0.000267	0.000922	CcSEcCtD
Dexrazoxane—Nervous system disorder—Paclitaxel—ovarian cancer	0.000266	0.00092	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000266	0.000918	CcSEcCtD
Dexrazoxane—Breast disorder—Doxorubicin—ovarian cancer	0.000264	0.000912	CcSEcCtD
Dexrazoxane—Skin disorder—Paclitaxel—ovarian cancer	0.000264	0.000911	CcSEcCtD
Dexrazoxane—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000263	0.000909	CcSEcCtD
Dexrazoxane—Anaemia—Docetaxel—ovarian cancer	0.000261	0.0009	CcSEcCtD
Dexrazoxane—Pancytopenia—Epirubicin—ovarian cancer	0.000259	0.000895	CcSEcCtD
Dexrazoxane—Anorexia—Paclitaxel—ovarian cancer	0.000259	0.000894	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—SKP2—ovarian cancer	0.000259	0.0229	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.000258	0.0229	CbGpPWpGaD
Dexrazoxane—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000258	0.00089	CcSEcCtD
Dexrazoxane—Vomiting—Vinorelbine—ovarian cancer	0.000257	0.000887	CcSEcCtD
Dexrazoxane—Neutropenia—Epirubicin—ovarian cancer	0.000255	0.000882	CcSEcCtD
Dexrazoxane—Headache—Vinorelbine—ovarian cancer	0.000253	0.000874	CcSEcCtD
Dexrazoxane—Syncope—Docetaxel—ovarian cancer	0.000253	0.000874	CcSEcCtD
Dexrazoxane—Dysphagia—Doxorubicin—ovarian cancer	0.000253	0.000872	CcSEcCtD
Dexrazoxane—Leukopenia—Docetaxel—ovarian cancer	0.000252	0.000872	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—TOP1—ovarian cancer	0.000248	0.0219	CbGpPWpGaD
Dexrazoxane—Loss of consciousness—Docetaxel—ovarian cancer	0.000248	0.000856	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000247	0.000854	CcSEcCtD
Dexrazoxane—Weight decreased—Epirubicin—ovarian cancer	0.000247	0.000853	CcSEcCtD
Dexrazoxane—Cough—Docetaxel—ovarian cancer	0.000246	0.00085	CcSEcCtD
Dexrazoxane—Insomnia—Paclitaxel—ovarian cancer	0.000246	0.000848	CcSEcCtD
Dexrazoxane—Pneumonia—Epirubicin—ovarian cancer	0.000245	0.000846	CcSEcCtD
Dexrazoxane—Infestation NOS—Epirubicin—ovarian cancer	0.000243	0.000841	CcSEcCtD
Dexrazoxane—Infestation—Epirubicin—ovarian cancer	0.000243	0.000841	CcSEcCtD
Dexrazoxane—Dyspnoea—Paclitaxel—ovarian cancer	0.000242	0.000836	CcSEcCtD
Dexrazoxane—Somnolence—Paclitaxel—ovarian cancer	0.000241	0.000834	CcSEcCtD
Dexrazoxane—Myalgia—Docetaxel—ovarian cancer	0.00024	0.000829	CcSEcCtD
Dexrazoxane—Pancytopenia—Doxorubicin—ovarian cancer	0.00024	0.000829	CcSEcCtD
Dexrazoxane—Nausea—Vinorelbine—ovarian cancer	0.00024	0.000828	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000238	0.000824	CcSEcCtD
Dexrazoxane—Stomatitis—Epirubicin—ovarian cancer	0.000237	0.000819	CcSEcCtD
Dexrazoxane—Neutropenia—Doxorubicin—ovarian cancer	0.000236	0.000816	CcSEcCtD
Dexrazoxane—Decreased appetite—Paclitaxel—ovarian cancer	0.000236	0.000815	CcSEcCtD
Dexrazoxane—Dry mouth—Docetaxel—ovarian cancer	0.000235	0.000811	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000234	0.00081	CcSEcCtD
Dexrazoxane—Fatigue—Paclitaxel—ovarian cancer	0.000234	0.000809	CcSEcCtD
Dexrazoxane—Constipation—Paclitaxel—ovarian cancer	0.000232	0.000802	CcSEcCtD
Dexrazoxane—Pain—Paclitaxel—ovarian cancer	0.000232	0.000802	CcSEcCtD
Dexrazoxane—Infection—Docetaxel—ovarian cancer	0.000229	0.00079	CcSEcCtD
Dexrazoxane—Weight decreased—Doxorubicin—ovarian cancer	0.000229	0.000789	CcSEcCtD
Dexrazoxane—Agranulocytosis—Epirubicin—ovarian cancer	0.000227	0.000785	CcSEcCtD
Dexrazoxane—Pneumonia—Doxorubicin—ovarian cancer	0.000227	0.000782	CcSEcCtD
Dexrazoxane—Shock—Docetaxel—ovarian cancer	0.000226	0.000782	CcSEcCtD
Dexrazoxane—Nervous system disorder—Docetaxel—ovarian cancer	0.000226	0.00078	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Docetaxel—ovarian cancer	0.000225	0.000778	CcSEcCtD
Dexrazoxane—Infestation—Doxorubicin—ovarian cancer	0.000225	0.000778	CcSEcCtD
Dexrazoxane—Infestation NOS—Doxorubicin—ovarian cancer	0.000225	0.000778	CcSEcCtD
Dexrazoxane—Feeling abnormal—Paclitaxel—ovarian cancer	0.000224	0.000773	CcSEcCtD
Dexrazoxane—Skin disorder—Docetaxel—ovarian cancer	0.000224	0.000772	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000222	0.000767	CcSEcCtD
Dexrazoxane—Haemoglobin—Epirubicin—ovarian cancer	0.00022	0.000759	CcSEcCtD
Dexrazoxane—Stomatitis—Doxorubicin—ovarian cancer	0.00022	0.000758	CcSEcCtD
Dexrazoxane—Anorexia—Docetaxel—ovarian cancer	0.000219	0.000758	CcSEcCtD
Dexrazoxane—Haemorrhage—Epirubicin—ovarian cancer	0.000219	0.000755	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—PPP1CC—ovarian cancer	0.000217	0.0192	CbGpPWpGaD
Dexrazoxane—Urticaria—Paclitaxel—ovarian cancer	0.000216	0.000745	CcSEcCtD
Dexrazoxane—Oedema peripheral—Epirubicin—ovarian cancer	0.000215	0.000743	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Epirubicin—ovarian cancer	0.000215	0.000742	CcSEcCtD
Dexrazoxane—Abdominal pain—Paclitaxel—ovarian cancer	0.000215	0.000741	CcSEcCtD
Dexrazoxane—Body temperature increased—Paclitaxel—ovarian cancer	0.000215	0.000741	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—RSF1—ovarian cancer	0.000213	0.0188	CbGpPWpGaD
Dexrazoxane—Agranulocytosis—Doxorubicin—ovarian cancer	0.00021	0.000726	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.00021	0.000724	CcSEcCtD
Dexrazoxane—Insomnia—Docetaxel—ovarian cancer	0.000208	0.000719	CcSEcCtD
Dexrazoxane—Dyspnoea—Docetaxel—ovarian cancer	0.000205	0.000709	CcSEcCtD
Dexrazoxane—Somnolence—Docetaxel—ovarian cancer	0.000205	0.000707	CcSEcCtD
Dexrazoxane—Haemoglobin—Doxorubicin—ovarian cancer	0.000203	0.000702	CcSEcCtD
Dexrazoxane—Cardiac disorder—Epirubicin—ovarian cancer	0.000203	0.0007	CcSEcCtD
Dexrazoxane—Haemorrhage—Doxorubicin—ovarian cancer	0.000202	0.000698	CcSEcCtD
Dexrazoxane—Decreased appetite—Docetaxel—ovarian cancer	0.0002	0.000691	CcSEcCtD
Dexrazoxane—Oedema peripheral—Doxorubicin—ovarian cancer	0.000199	0.000688	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000199	0.000686	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000199	0.000686	CcSEcCtD
Dexrazoxane—Fatigue—Docetaxel—ovarian cancer	0.000198	0.000685	CcSEcCtD
Dexrazoxane—Angiopathy—Epirubicin—ovarian cancer	0.000198	0.000685	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Epirubicin—ovarian cancer	0.000197	0.00068	CcSEcCtD
Dexrazoxane—Constipation—Docetaxel—ovarian cancer	0.000197	0.00068	CcSEcCtD
Dexrazoxane—Pain—Docetaxel—ovarian cancer	0.000197	0.00068	CcSEcCtD
Dexrazoxane—Asthenia—Paclitaxel—ovarian cancer	0.000195	0.000673	CcSEcCtD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—CTNNB1—ovarian cancer	0.000194	0.0172	CbGpPWpGaD
Dexrazoxane—Alopecia—Epirubicin—ovarian cancer	0.000193	0.000667	CcSEcCtD
Dexrazoxane—Pruritus—Paclitaxel—ovarian cancer	0.000192	0.000664	CcSEcCtD
Dexrazoxane—Mental disorder—Epirubicin—ovarian cancer	0.000191	0.000661	CcSEcCtD
Dexrazoxane—Malnutrition—Epirubicin—ovarian cancer	0.00019	0.000657	CcSEcCtD
Dexrazoxane—Erythema—Epirubicin—ovarian cancer	0.00019	0.000657	CcSEcCtD
Dexrazoxane—Feeling abnormal—Docetaxel—ovarian cancer	0.00019	0.000655	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000188	0.00065	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—HNF1B—ovarian cancer	0.000188	0.0166	CbGpPWpGaD
Dexrazoxane—Cardiac disorder—Doxorubicin—ovarian cancer	0.000188	0.000648	CcSEcCtD
Dexrazoxane—Diarrhoea—Paclitaxel—ovarian cancer	0.000186	0.000642	CcSEcCtD
Dexrazoxane—Angiopathy—Doxorubicin—ovarian cancer	0.000183	0.000634	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000182	0.000629	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—SKP2—ovarian cancer	0.000182	0.0161	CbGpPWpGaD
Dexrazoxane—Abdominal pain—Docetaxel—ovarian cancer	0.000182	0.000628	CcSEcCtD
Dexrazoxane—Body temperature increased—Docetaxel—ovarian cancer	0.000182	0.000628	CcSEcCtD
Dexrazoxane—Dizziness—Paclitaxel—ovarian cancer	0.00018	0.00062	CcSEcCtD
Dexrazoxane—Alopecia—Doxorubicin—ovarian cancer	0.000179	0.000617	CcSEcCtD
Dexrazoxane—Mental disorder—Doxorubicin—ovarian cancer	0.000177	0.000612	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Epirubicin—ovarian cancer	0.000176	0.00061	CcSEcCtD
Dexrazoxane—Malnutrition—Doxorubicin—ovarian cancer	0.000176	0.000608	CcSEcCtD
Dexrazoxane—Erythema—Doxorubicin—ovarian cancer	0.000176	0.000608	CcSEcCtD
Dexrazoxane—Anaemia—Epirubicin—ovarian cancer	0.000176	0.000607	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CCNE1—ovarian cancer	0.000174	0.0154	CbGpPWpGaD
Dexrazoxane—Vomiting—Paclitaxel—ovarian cancer	0.000173	0.000596	CcSEcCtD
Dexrazoxane—Malaise—Epirubicin—ovarian cancer	0.000172	0.000592	CcSEcCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—TYMS—ovarian cancer	0.000171	0.0151	CbGpPWpGaD
Dexrazoxane—Syncope—Epirubicin—ovarian cancer	0.000171	0.000589	CcSEcCtD
Dexrazoxane—Leukopenia—Epirubicin—ovarian cancer	0.00017	0.000588	CcSEcCtD
Dexrazoxane—Headache—Paclitaxel—ovarian cancer	0.00017	0.000588	CcSEcCtD
Dexrazoxane—Loss of consciousness—Epirubicin—ovarian cancer	0.000167	0.000577	CcSEcCtD
Dexrazoxane—Cough—Epirubicin—ovarian cancer	0.000166	0.000573	CcSEcCtD
Dexrazoxane—Asthenia—Docetaxel—ovarian cancer	0.000165	0.00057	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000163	0.000564	CcSEcCtD
Dexrazoxane—Pruritus—Docetaxel—ovarian cancer	0.000163	0.000562	CcSEcCtD
Dexrazoxane—Anaemia—Doxorubicin—ovarian cancer	0.000163	0.000562	CcSEcCtD
Dexrazoxane—Myalgia—Epirubicin—ovarian cancer	0.000162	0.000559	CcSEcCtD
Dexrazoxane—Nausea—Paclitaxel—ovarian cancer	0.000161	0.000557	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000161	0.000555	CcSEcCtD
Dexrazoxane—Discomfort—Epirubicin—ovarian cancer	0.00016	0.000553	CcSEcCtD
Dexrazoxane—Malaise—Doxorubicin—ovarian cancer	0.000159	0.000548	CcSEcCtD
Dexrazoxane—Dry mouth—Epirubicin—ovarian cancer	0.000158	0.000547	CcSEcCtD
Dexrazoxane—Syncope—Doxorubicin—ovarian cancer	0.000158	0.000545	CcSEcCtD
Dexrazoxane—Leukopenia—Doxorubicin—ovarian cancer	0.000158	0.000544	CcSEcCtD
Dexrazoxane—Diarrhoea—Docetaxel—ovarian cancer	0.000157	0.000544	CcSEcCtD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—MYC—ovarian cancer	0.000157	0.0139	CbGpPWpGaD
Dexrazoxane—Loss of consciousness—Doxorubicin—ovarian cancer	0.000155	0.000534	CcSEcCtD
Dexrazoxane—Infection—Epirubicin—ovarian cancer	0.000154	0.000533	CcSEcCtD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—EGFR—ovarian cancer	0.000154	0.0136	CbGpPWpGaD
Dexrazoxane—Cough—Doxorubicin—ovarian cancer	0.000154	0.00053	CcSEcCtD
Dexrazoxane—Shock—Epirubicin—ovarian cancer	0.000153	0.000528	CcSEcCtD
Dexrazoxane—Nervous system disorder—Epirubicin—ovarian cancer	0.000152	0.000526	CcSEcCtD
Dexrazoxane—Dizziness—Docetaxel—ovarian cancer	0.000152	0.000526	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Epirubicin—ovarian cancer	0.000152	0.000525	CcSEcCtD
Dexrazoxane—Skin disorder—Epirubicin—ovarian cancer	0.000151	0.000521	CcSEcCtD
Dexrazoxane—Myalgia—Doxorubicin—ovarian cancer	0.00015	0.000518	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000149	0.000514	CcSEcCtD
Dexrazoxane—Discomfort—Doxorubicin—ovarian cancer	0.000148	0.000511	CcSEcCtD
Dexrazoxane—Anorexia—Epirubicin—ovarian cancer	0.000148	0.000511	CcSEcCtD
Dexrazoxane—Dry mouth—Doxorubicin—ovarian cancer	0.000147	0.000506	CcSEcCtD
Dexrazoxane—Vomiting—Docetaxel—ovarian cancer	0.000146	0.000505	CcSEcCtD
Dexrazoxane—Headache—Docetaxel—ovarian cancer	0.000144	0.000498	CcSEcCtD
Dexrazoxane—Infection—Doxorubicin—ovarian cancer	0.000143	0.000493	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000141	0.000489	CcSEcCtD
Dexrazoxane—Shock—Doxorubicin—ovarian cancer	0.000141	0.000488	CcSEcCtD
Dexrazoxane—Nervous system disorder—Doxorubicin—ovarian cancer	0.000141	0.000487	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000141	0.000486	CcSEcCtD
Dexrazoxane—Insomnia—Epirubicin—ovarian cancer	0.00014	0.000485	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCND2—ovarian cancer	0.00014	0.0123	CbGpPWpGaD
Dexrazoxane—Skin disorder—Doxorubicin—ovarian cancer	0.00014	0.000482	CcSEcCtD
Dexrazoxane—Dyspnoea—Epirubicin—ovarian cancer	0.000138	0.000478	CcSEcCtD
Dexrazoxane—Somnolence—Epirubicin—ovarian cancer	0.000138	0.000477	CcSEcCtD
Dexrazoxane—Anorexia—Doxorubicin—ovarian cancer	0.000137	0.000473	CcSEcCtD
Dexrazoxane—Nausea—Docetaxel—ovarian cancer	0.000137	0.000472	CcSEcCtD
Dexrazoxane—Decreased appetite—Epirubicin—ovarian cancer	0.000135	0.000466	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000134	0.000463	CcSEcCtD
Dexrazoxane—Fatigue—Epirubicin—ovarian cancer	0.000134	0.000462	CcSEcCtD
Dexrazoxane—Constipation—Epirubicin—ovarian cancer	0.000133	0.000459	CcSEcCtD
Dexrazoxane—Pain—Epirubicin—ovarian cancer	0.000133	0.000459	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—PPP2R1A—ovarian cancer	0.000132	0.0116	CbGpPWpGaD
Dexrazoxane—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000131	0.000452	CcSEcCtD
Dexrazoxane—Insomnia—Doxorubicin—ovarian cancer	0.00013	0.000449	CcSEcCtD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—TP53—ovarian cancer	0.000129	0.0114	CbGpPWpGaD
Dexrazoxane—Dyspnoea—Doxorubicin—ovarian cancer	0.000128	0.000442	CcSEcCtD
Dexrazoxane—Feeling abnormal—Epirubicin—ovarian cancer	0.000128	0.000442	CcSEcCtD
Dexrazoxane—Somnolence—Doxorubicin—ovarian cancer	0.000128	0.000441	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000127	0.000438	CcSEcCtD
Dexrazoxane—Decreased appetite—Doxorubicin—ovarian cancer	0.000125	0.000431	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000124	0.000428	CcSEcCtD
Dexrazoxane—Fatigue—Doxorubicin—ovarian cancer	0.000124	0.000428	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.000123	0.0109	CbGpPWpGaD
Dexrazoxane—Urticaria—Epirubicin—ovarian cancer	0.000123	0.000426	CcSEcCtD
Dexrazoxane—Pain—Doxorubicin—ovarian cancer	0.000123	0.000424	CcSEcCtD
Dexrazoxane—Constipation—Doxorubicin—ovarian cancer	0.000123	0.000424	CcSEcCtD
Dexrazoxane—Abdominal pain—Epirubicin—ovarian cancer	0.000123	0.000424	CcSEcCtD
Dexrazoxane—Body temperature increased—Epirubicin—ovarian cancer	0.000123	0.000424	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCNE1—ovarian cancer	0.000122	0.0108	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—TYMS—ovarian cancer	0.00012	0.0106	CbGpPWpGaD
Dexrazoxane—Feeling abnormal—Doxorubicin—ovarian cancer	0.000118	0.000409	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000117	0.000406	CcSEcCtD
Dexrazoxane—Urticaria—Doxorubicin—ovarian cancer	0.000114	0.000394	CcSEcCtD
Dexrazoxane—Body temperature increased—Doxorubicin—ovarian cancer	0.000114	0.000392	CcSEcCtD
Dexrazoxane—Abdominal pain—Doxorubicin—ovarian cancer	0.000114	0.000392	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000113	0.00998	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—RAD51C—ovarian cancer	0.000112	0.00989	CbGpPWpGaD
Dexrazoxane—Asthenia—Epirubicin—ovarian cancer	0.000111	0.000385	CcSEcCtD
Dexrazoxane—Pruritus—Epirubicin—ovarian cancer	0.00011	0.000379	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—PPP1CC—ovarian cancer	0.000109	0.00967	CbGpPWpGaD
Dexrazoxane—Diarrhoea—Epirubicin—ovarian cancer	0.000106	0.000367	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000106	0.00935	CbGpPWpGaD
Dexrazoxane—Asthenia—Doxorubicin—ovarian cancer	0.000103	0.000356	CcSEcCtD
Dexrazoxane—Dizziness—Epirubicin—ovarian cancer	0.000103	0.000355	CcSEcCtD
Dexrazoxane—Pruritus—Doxorubicin—ovarian cancer	0.000102	0.000351	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—RBL2—ovarian cancer	0.0001	0.00888	CbGpPWpGaD
Dexrazoxane—Vomiting—Epirubicin—ovarian cancer	9.87e-05	0.000341	CcSEcCtD
Dexrazoxane—Diarrhoea—Doxorubicin—ovarian cancer	9.83e-05	0.000339	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—PPP1CC—ovarian cancer	9.77e-05	0.00865	CbGpPWpGaD
Dexrazoxane—Headache—Epirubicin—ovarian cancer	9.73e-05	0.000336	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	9.56e-05	0.00846	CbGpPWpGaD
Dexrazoxane—Dizziness—Doxorubicin—ovarian cancer	9.5e-05	0.000328	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	9.26e-05	0.00819	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	9.26e-05	0.00819	CbGpPWpGaD
Dexrazoxane—Nausea—Epirubicin—ovarian cancer	9.22e-05	0.000318	CcSEcCtD
Dexrazoxane—Vomiting—Doxorubicin—ovarian cancer	9.13e-05	0.000315	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	9.09e-05	0.00805	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—ovarian cancer	9e-05	0.00797	CbGpPWpGaD
Dexrazoxane—Headache—Doxorubicin—ovarian cancer	9e-05	0.000311	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—RBL2—ovarian cancer	8.97e-05	0.00794	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—TYMS—ovarian cancer	8.73e-05	0.00772	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—ovarian cancer	8.59e-05	0.0076	CbGpPWpGaD
Dexrazoxane—Nausea—Doxorubicin—ovarian cancer	8.53e-05	0.000295	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	7.06e-05	0.00625	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—MYC—ovarian cancer	6.89e-05	0.0061	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—SKP2—ovarian cancer	6.68e-05	0.00591	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	6.67e-05	0.0059	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN1B—ovarian cancer	6.34e-05	0.0056	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCND1—ovarian cancer	6.04e-05	0.00535	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MLH1—ovarian cancer	6.04e-05	0.00534	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—SKP2—ovarian cancer	5.97e-05	0.00528	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—TP53—ovarian cancer	5.66e-05	0.00501	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	5.18e-05	0.00458	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCND2—ovarian cancer	5.12e-05	0.00453	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CHEK2—ovarian cancer	4.88e-05	0.00432	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—MYC—ovarian cancer	4.85e-05	0.00429	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—PPP2R1A—ovarian cancer	4.83e-05	0.00427	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	4.8e-05	0.00425	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	4.7e-05	0.00416	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	4.58e-05	0.00405	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—BRCA1—ovarian cancer	4.58e-05	0.00405	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CCND2—ovarian cancer	4.58e-05	0.00405	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	4.53e-05	0.00401	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCNE1—ovarian cancer	4.48e-05	0.00397	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	4.42e-05	0.00391	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—TYMS—ovarian cancer	4.4e-05	0.00389	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—PPP2R1A—ovarian cancer	4.32e-05	0.00382	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—PTEN—ovarian cancer	4.24e-05	0.00375	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—BRCA2—ovarian cancer	4.14e-05	0.00366	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CCNE1—ovarian cancer	4.01e-05	0.00355	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	3.99e-05	0.00353	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—BIRC5—ovarian cancer	3.96e-05	0.0035	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TYMS—ovarian cancer	3.94e-05	0.00348	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	3.78e-05	0.00334	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	3.67e-05	0.00325	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	3.59e-05	0.00318	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	3.59e-05	0.00318	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—BIRC5—ovarian cancer	3.54e-05	0.00313	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TERT—ovarian cancer	3.43e-05	0.00303	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	3.39e-05	0.003	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	3.12e-05	0.00276	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	3.02e-05	0.00267	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—TP53—ovarian cancer	2.9e-05	0.00256	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—IL6—ovarian cancer	2.65e-05	0.00234	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	2.55e-05	0.00225	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN1B—ovarian cancer	2.32e-05	0.00206	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCND1—ovarian cancer	2.22e-05	0.00196	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDKN1B—ovarian cancer	2.08e-05	0.00184	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CCND1—ovarian cancer	1.98e-05	0.00175	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MAPK3—ovarian cancer	1.83e-05	0.00162	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MYC—ovarian cancer	1.78e-05	0.00157	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MAPK1—ovarian cancer	1.74e-05	0.00154	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MAPK3—ovarian cancer	1.63e-05	0.00145	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MYC—ovarian cancer	1.59e-05	0.00141	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MAPK1—ovarian cancer	1.56e-05	0.00138	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TP53—ovarian cancer	1.31e-05	0.00116	CbGpPWpGaD
